Overview

Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
0
Participant gender:
All
Summary
Observational study to compare the treatment in neutropenic patients after allogenic blood stem cell transplantation, with meropenem or meropenem plus glycopeptide.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
PETHEMA Foundation
Treatments:
Meropenem
Teicoplanin
Thienamycins
Vancomycin
Criteria
Inclusion Criteria:

- Age > 18 years

- Patients submitted to allogenic transplant

- Neutropenia: neutrophils account < 500/mm3 or neutrophils account < 1000/mm3 with
prevision to decrease until 500/mm3 at the next 24-48 h

- Signs and symptoms to infection

- Fever: Temperature> 38,3 ºC registered one time, or 38 ºC en two times separated 60
minutes in a period of 12 h.

Exclusion Criteria:

- Medical history of meropenem or glycopeptides hypersensitivity

- Renal failure or creatinine in serum > 2,25 mg/dl or creatinine clearance < 40 ml

- Liver insufficiency

- Childbearing potential or breast feeding period

- Contraindications to meropenem, vancomycin or teicoplanin